Leukadherin 1

SKU: orb1225242

Description

Leukadherin 1 (LA1) is a small molecule allosteric agonist of integrin CD11b/CD18 (CR3), increases CD11b/CD18-dependent cell adhesion to fibrinogen (EC50=4 uM); reduces IFN-I responses in WT but not CD11b-deficient mice, and protects lupus-prone MRL/Lpr mice from end-organ injury; reduces TLR-dependent proinflammatory signaling in leukocytes and suppresses IFN-I signaling via an AKT/FOXO3/IFN regulatory factor 3/7 pathway.

Key Properties

• CAS Number: 344897-95-6
• MW: 421.49
• Purity: >98% (HPLC)
• Formula: C₂₂H₁₅NO₄S₂
• SMILES: O=C(O)C1=CC=C(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)/C3=O)O2)C=C1
• Target: Complement System
• Solubility: DMSO: 15 mg/mL (35.59 mM); Water: <1 mg/mL; Ethanol: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

Bioactivity

• In Vivo:
  Leukadherin-1 (1 mg/kg; i.p.; twice daily for 14 days) is beneficial in preventing hyperoxia-induced neonatal lung injury, an experimental model of bronchopulmonary dysplasia (BPD). Animal model: Newborn Sprague Dawley rat pups. Dosage: 1 mg/kg. Administration: i.p.; twice daily for 14 days. Result: Beneficial on preventing the lung inflammatory response, improved alveolarization and vascular development, and reduced pulmonary vascular remodeling and PH in a hyperoxia-induced experimental model of BPD.
• In Vitro:
  Leukadherin-1 is a specific agonist of the leukocyte surface integrin CD11b/CD18 (αMβ2; CR3; Mac-1). Leukadherin‐1 pretreatment reduces secretion of interferon (IFN)‐γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)‐1β by monokine‐stimulated NK cells. Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LA1

Quick Database Links

Gene Symbol

Complement System